{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:09Z","timestamp":1753891989072,"version":"3.41.2"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>AK111 is an innovative IL-17A antibody, presenting high affinity to IL-17A and showing similar pharmacokinetic (PK) characteristics to those of typical immunoglobulin (Ig) G1 antibodies. To optimize the dosage regimen for phase 2\/3 clinical trials, PK and pharmacodynamics (PD) of AK111 were first characterized in Chinese moderate-to-severe plaque psoriasis patients in a phase 1b study. AK111 PK serum sample and Psoriasis Area and Severity Index (PASI) score data were collected from 48 moderate-to-severe psoriasis patients in this study. Non-linear mixed-effects modeling was used for the population PK\/PD analysis. A one-compartment model with a first-order absorption and a first-order elimination best described the PK behavior of AK111. The apparent systemic clearance was 0.182\u00a0L\/day, and the central volume was 6.65\u00a0L. The exposure\u2013response relationship was characterized using an indirect response model. The pharmacological effect of AK111 was described in the form of inhibiting the formation of psoriatic plaque, whereas placebo was quantified in the form of promoting the degradation of psoriatic skin lesions. The maximum effect of drug effect (I<jats:sub>max<\/jats:sub>) and placebo effect (PLB<jats:sub>max<\/jats:sub>) was 1 and 0.429, respectively. The rate constant for psoriatic plaque production (K<jats:sub>in<\/jats:sub>) was 0.474 PASI\/day and psoriatic plaque loss (K<jats:sub>out<\/jats:sub>) was 0.024\u00a0day<jats:sup>\u22121<\/jats:sup>. The body surface area (BSA) affected by psoriasis was identified as a significant covariate on <jats:inline-formula><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"m1\"><mml:mrow><mml:msub><mml:mi>K<\/mml:mi><mml:mrow><mml:mi>o<\/mml:mi><mml:mi>u<\/mml:mi><mml:mi>t<\/mml:mi><\/mml:mrow><\/mml:msub><\/mml:mrow><\/mml:math><\/jats:inline-formula>. The simulation results confirmed that all of the predicted PASI90 response rates at week 12 were higher than 60% at 150 and 300\u00a0mg dose levels with different regimens and could reach higher than 80% at week 24. We hope this first PK\/PD study of AK111 in Chinese moderate-to-severe plaque psoriasis patients will be of help in the further clinical development of AK111 and provide a reference to the dosage optimization for similar antibodies with a long half-life.<\/jats:p>","DOI":"10.3389\/fphar.2022.966176","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T05:35:39Z","timestamp":1660628139000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Population pharmacokinetic\/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis"],"prefix":"10.3389","volume":"13","author":[{"given":"Qian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benchao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","article-title":"Clinical measures of disease severity and outcome in psoriasis: A critical appraisal of their quality","volume":"141","author":"Ashcroft","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, Secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J. Immunol. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1046\/j.0306-5251.2001.01410.x","article-title":"Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients","volume":"52","author":"Bellissant","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/jcph.876","article-title":"Population pharmacokinetic modeling of Secukinumab in patients with moderate to severe psoriasis","volume":"57","author":"Bruin","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/14712598.2020.1729736","article-title":"Ixekizumab for the treatment of psoriasis: Up-to-date","volume":"20","author":"Craig","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J. Invest. Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40360-020-00419-0","article-title":"18\u03b2-Glycyrrhetinic acid induces human HaCaT keratinocytes apoptosis through ROS-mediated PI3K-Akt signaling pathway and ameliorates IMQ-induced psoriasis-like skin lesions in mice","volume":"21","author":"Gao","year":"2020","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fphar.2020.00117","article-title":"Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities","volume":"11","author":"Gisondi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10928-018-9581-1","article-title":"A comprehensive evaluation of exposure-response relationships in clinical trials: Application to support guselkumab dose selection for patients with psoriasis","volume":"45","author":"Hu","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/0091270006295062","article-title":"Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis","volume":"47","author":"Hutmacher","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/bcp.15034","article-title":"Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)","volume":"88","author":"Jackson","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e00131","DOI":"10.1002\/prp2.131","article-title":"Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses","volume":"3","author":"Keizer","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"B16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/cpt.1594","article-title":"Exposure-response relationships for efficacy and safety of risankizumab in phase II and III trials in psoriasis patients","volume":"107","author":"Khatri","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","first-page":"1","article-title":"Ultraviolet phototherapy management of moderate-to-severe plaque psoriasis: An evidence-based analysis","volume":"9","year":"2009","journal-title":"Ont. Health Technol. Assess. Ser."},{"key":"B18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.04411.x","article-title":"Implementing treatment goals for successful long-term management of psoriasis","volume":"26","author":"Mrowietz","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: A European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/jdv.17130","article-title":"Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values \u22641, 2, 3 or 5 derived from a statistical conversion method","volume":"35","author":"Mrowietz","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/psp4.12015","article-title":"Establishing good practices for exposure-response analysis of clinical endpoints in drug development","volume":"4","author":"Overgaard","year":"2015","journal-title":"CPT. Pharmacometrics Syst. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/cts.12725","article-title":"Using real-world data to guide ustekinumab dosing strategies for psoriasis: A prospective pharmacokinetic-pharmacodynamic study","volume":"13","author":"Pan","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jdv.12817","article-title":"PASI90 response: The new standard in therapeutic efficacy for psoriasis","volume":"29","author":"Puig","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.3390\/pharmaceutics14030654","article-title":"Impact of pharmacokinetic and pharmacodynamic properties of monoclonal antibodies in the management of psoriasis","volume":"14","author":"Rodriguez-Fernandez","year":"2022","journal-title":"Pharmaceutics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/cpdd.103","article-title":"A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study","volume":"3","author":"Salinger","year":"2014","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40262-019-00829-2","article-title":"Exposure-response relationships for the efficacy and safety of risankizumab in Japanese subjects with psoriasis","volume":"59","author":"Suleiman","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/jcph.312","article-title":"Population exposure-response model to support dosing evaluation of ixekizumab in patients with chronic plaque psoriasis","volume":"54","author":"Tham","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fphar.2014.00174","article-title":"Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research","volume":"5","author":"Tuntland","year":"2014","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0091270009343695","article-title":"Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis","volume":"50","author":"Zhou","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9154","DOI":"10.1038\/s41598-020-65689-4","article-title":"Assessing the severity of psoriasis through multivariate analysis of optical images from non-lesional skin","volume":"10","author":"Zurauskas","year":"2020","journal-title":"Sci. Rep."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.966176\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T05:35:47Z","timestamp":1660628147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.966176\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":32,"alternative-id":["10.3389\/fphar.2022.966176"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.966176","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"article-number":"966176"}}